Yale University School of Medicine, Department of Medicine, New Haven, CT (G.V.D., L.Q.T., P.W., G.L., H.V.) ; VA Connecticut Healthcare System (VACHS) Medical Center, West Haven, CT (G.V.D., L.Q.T., P.W., G.L., H.V.).
J Am Heart Assoc. 2012 Aug;1(4):e002634. doi: 10.1161/JAHA.112.002634. Epub 2012 Aug 24.
Blood pressure is acutely regulated by the sympathetic nervous system through the action of vasoactive hormones such as epinephrine, norepinephrine, and dopamine. Renalase, a recently described, secreted flavoprotein, acutely decreases systemic pressure when administered in vivo. Single-nucleotide polymorphisms present in the gene are associated with hypertension, cardiac disease, and diabetes. Although renalase's crystal structure was recently solved, its natural substrate(s) remains undefined.
Using in vitro enzymatic assays and in vivo administration of recombinant renalase, we show that the protein functions as a flavin adenine dinucleotide- and nicotinamide adenine dinucleotide-dependent oxidase that lowers blood pressure by degrading plasma epinephrine. The enzyme also metabolizes the dopamine precursor l-3,4-dihydroxyphenylalanine but has low activity against dopamine and does not metabolize norepinephrine. To test if epinephrine and l-3,4-dihydroxyphenylalanine were renalase's only substrates, 17 246 unique small molecules were screened. Although the search revealed no additional, naturally occurring compounds, it identified dobutamine, isoproterenol, and α-methyldopa as substrates of renalase. Mutational analysis was used to test if renalase's hypotensive effect correlated with its enzymatic activity. Single-amino acid mutations that decrease its enzymatic activity to varying degrees comparably reduce its hypotensive effect.
Renalase metabolizes circulating epinephrine and l-3,4-dihydroxyphenylalanine, and its capacity to decrease blood pressure is directly correlated to its enzymatic activity. These findings highlight a previously unrecognized mechanism for epinephrine metabolism and blood pressure regulation, expand our understanding of the sympathetic nervous system, and could lead to the development of novel therapeutic modalities for the treatment of hypertension. (J Am Heart Assoc. 2012;1:e002634 doi: 10.1161/JAHA.112.002634.).
血压通过血管活性激素(如肾上腺素、去甲肾上腺素和多巴胺)的作用被交感神经系统急性调节。肾酶是一种最近描述的分泌性黄素蛋白,当体内给药时,可急性降低全身血压。基因中存在的单核苷酸多态性与高血压、心脏病和糖尿病有关。尽管肾酶的晶体结构最近已经解决,但它的天然底物仍然未知。
我们使用体外酶促测定法和体内给予重组肾酶,表明该蛋白作为黄素腺嘌呤二核苷酸和烟酰胺腺嘌呤二核苷酸依赖性氧化酶发挥作用,通过降解血浆肾上腺素来降低血压。该酶还代谢多巴胺前体 l-3,4-二羟基苯丙氨酸,但对多巴胺的活性低,不代谢去甲肾上腺素。为了测试肾上腺素和 l-3,4-二羟基苯丙氨酸是否是肾酶的唯一底物,筛选了 17246 种独特的小分子。虽然搜索没有发现其他天然存在的化合物,但它确定了肾上腺素和 l-3,4-二羟基苯丙氨酸是肾酶的底物。突变分析用于测试肾酶的降压作用是否与其酶活性相关。降低其酶活性程度不同的单氨基酸突变同样降低其降压作用。
肾酶代谢循环中的肾上腺素和 l-3,4-二羟基苯丙氨酸,其降低血压的能力与其酶活性直接相关。这些发现强调了肾上腺素代谢和血压调节的一个以前未被认识的机制,扩展了我们对交感神经系统的理解,并可能导致治疗高血压的新治疗方法的发展。